Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE and NK Immunotherapy for Recurrent Liver Cancer
NCT03008343Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural Killer Cells in hepatocellular carcinoma (HCC), sponsored by Fuda Cancer Hospital. Started Dec 2016; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03008343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008343.